Main menu

Pfizer Settles Viagra® Patent Litigation With Teva

Tuesday, December 17, 2013 - 11:55am EST

Pfizer Inc. announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer’s patent covering the use of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and 100 mg tablets), which expires in April 2020 (including pediatric exclusivity).  As a result of the settlement, Teva will be allowed to launch a generic version of Viagra® in the United States on December 11, 2017, or earlier under certain circumstances.  Teva will pay Pfizer a royalty for a license to produce its generic version.  The terms of the settlement agreement are otherwise confidential.  Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Viagra®.  

 

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.  We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.  Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

Contact:

Media Contact:
Chris Loder
(212) 733-7897
 
Investor Contact:
Charles Triano
(212) 733-3901